Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.5 GBX | +3.40% | +3.40% | -20.65% |
May. 15 | Creo Medical on track to break even next year on strong 2023 results | AN |
May. 15 | Creo Medical Group PLC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2023 | 30.8M 39.16M | Sales 2024 * | 40.37M 51.33M | Capitalization | 123M 156M |
---|---|---|---|---|---|
Net income 2023 | -21M -26.7M | Net income 2024 * | -14M -17.8M | EV / Sales 2023 | 5.2 x |
Net cash position 2023 * | 22.03M 28.01M | Net cash position 2024 * | 132K 168K | EV / Sales 2024 * | 3.04 x |
P/E ratio 2023 |
-6.57
x | P/E ratio 2024 * |
-9.05
x | Employees | 279 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 79.14% |
1 day | +3.40% | ||
1 week | +3.40% | ||
Current month | +1.39% | ||
1 month | +5.04% | ||
3 months | +8.96% | ||
6 months | +11.45% | ||
Current year | -20.65% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | - | |
Craig Gulliford
CEO | Chief Executive Officer | - | 11-12-31 |
President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Spicer
CHM | Chairman | 59 | 16-06-30 |
John Bradshaw
BRD | Director/Board Member | 60 | - |
Craig Gulliford
CEO | Chief Executive Officer | - | 11-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 36.5 | +3.40% | 1 088 936 |
24-05-17 | 35.3 | +6.97% | 1,320,816 |
24-05-16 | 33 | +1.54% | 3,060,522 |
24-05-15 | 32.5 | -6.88% | 2,385,634 |
24-05-14 | 34.9 | -1.13% | 691,016 |
Delayed Quote London S.E., May 20, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.65% | 156M | |
+73.26% | 12.39B | |
-20.29% | 7.89B | |
+8.15% | 6.59B | |
+12.49% | 5.43B | |
+40.80% | 4.96B | |
-17.45% | 4.72B | |
-18.76% | 4.02B | |
-28.88% | 2.66B | |
+61.62% | 2.37B |
- Stock Market
- Equities
- CREO Stock